Antivascular Effects of EphA 2 Reduction With an Agonistic Antibody in Ovarian Cancer

Charles N. Landen,Chunhua Lu,Liz Y. Han,Karen T. Coffman,Elizabeth Bruckheimer,Jyotsnabaran Halder,Lingegowda S. Mangala,William M. Merritt,Yvonne G. Lin,Changhou Gao,Rosemarie Schmandt,Aparna A. Kamat,Yang Li,Premal Thaker,David M. Gershenson,Nila U. Parikh,Gary E. Gallick,Michael S. Kinch,Anil K. Sood

2006-01-01

Abstract:Ovarian cancer remains the most common cause of death from gynecologic malignancy ( 1 ) . Approximately 75% of patients present with stage III or IV disease ( 2 , 3 ) , and the 5-year survival of such patients remains low, at 11% – 31% ( 1 , 3 ) . Although most patients with advanced-stage disease will die of the disease, more than 70% have a favorable initial response to surgery and chemotherapy and a substantial fraction will respond to second-line therapies. Biologically targeted therapies, such as cetuximab, bevacizumab, trastuzumab, and imatinib, have led to favorable responses in cancer therapy ( 4 – 7 ) and are being used in clinical trials for ovarian cancer. Many of these new compounds target receptor protein tyrosine kinases, which provide potent signals that often favor cell growth and survival. Among this class of targets, several independent lines of investigation have converged on the idea that the EphA2 receptor tyrosine kinase might provide a strong candidate for targeted intervention against cancer ( 8 – 10 ) . EphA2 was fi rst linked with neuronal migration during embryonic development ( 11 – 14 ) . Subsequently, many tumor cells have been shown to overexpress this protein, and high levels of EphA2 are suffi cient to promote many different aspects of a malignant phenotype, including proliferation, survival, migration, invasion, and angiogenesis ( 9 , 15 – 21 ) . EphA2 overexpression has been observed in many human cancers, including lung, breast, prostate, colorectal, melanoma, and esophageal malignancies ( 15 , 20 , 22 – 29 ) . EphA2 overexpression is common in ovarian cancer, relates to disease severity, and is predictive of poor outcome in patients with ovarian cancer ( 30 ) . In addition, EphA2 overexpression leads to its constitutive association with a number of signaling molecules including focal adhesion kinase ( 31 ) , which is also commonly overexpressed in ovarian carcinomas ( 30 ) . Consistent with these fi ndings, recent studies have demonstrated that reducing EphA2 levels is effective Background: EphA2 is an oncoprotein and tyrosine kinase receptor that is overexpressed in ovarian and many other cancers. We investigated the effects of reduced EphA2 levels on tumor growth and the tumor microenvironment in an orthotopic ovarian cancer model. Methods: The effect of the EphA2-agonistic monoclonal antibody EA5, alone or in combination with paclitaxel, on the growth of ovarian cancer cells (SKOV3ip1, HeyA8, and HeyA8MDR [taxane – platinum resistant]) was determined in vitro and in vivo by immunoblotting, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay, and immunohistochemical analysis. Expression of EphA2 and markers of angiogenesis (CD31, vascular endothelial growth factor [VEGF], and basic fi broblast growth factor), proliferation (proliferating cell nuclear antigen), and endothelial cell apoptosis (CD31 – terminal deoxynucleotidyl transferase biotin – deoxyuridine triphosphate nick-end labeling colocalization) and phosphorylation of Src were analyzed by immunoblotting, im munohistochemistry, immunofl uorescence, and in situ hybridization in tumors from treated mice. Statistical tests were two-sided. Results: EA5 antibody treatment led to a more than 90% reduction in EphA2 expression in HeyA8 tumors in vivo. In mice bearing orthotopic SKOV3ip1 or HeyA8 tumors, 4 weeks of EA5 treatment resulted in tumors that weighed 31% and 45% less, respectively, than those in control (IgG-treated) mice (95% confi dence interval [CI] = − 0.09% to 71% and 20% to 70%, P = .27 and .01, respectively). Combination therapy with EA5 and paclitaxel reduced tumor weight by 77% and 80% (95% CI = 63% to 91% and 68% to 91%), respectively, compared with paclitaxel alone and by 92% and 88% (95% CI = 87% to 97% and 80% to 94%), respectively, compared with IgG alone. Combination therapy also reduced the weight of HeyA8MDR tumors by 47% (95% CI = 24% to 72%) compared with paclitaxel. Mice bearing SKOV3ip1 or HeyA8 tumors that were treated with combination therapy survived longer than those treated with paclitaxel alone (median survival = 144 versus 69 days and 46 versus 37 days, respectively). EA5treated tumors had reduced microvascular density, proliferation, and VEGF protein and mRNA levels, with increased endothelial cell apoptosis. EphA2 was associated with Src, which was rapidly dephosphorylated after EA5 treatment. Conclusions: EA5 in combination with paclitaxel decreased tumor growth in an orthotopic ovarian cancer mouse model through antiangiogenic mechanisms associated with reduced levels of VEGF and phosphorylated Src. Humanized antiAffi liations of authors: Departments of Gynecologic Oncology (CNL, CL, LYH, JH, LSM, WMM, YGL, RS, AAK, YL, PT, DMG, AKS) and Cancer Biology (NUP, GEG, AKS), The University of Texas M. D. Anderson Cancer Center, Houston, TX; MedImmune, Inc, Gaithersburg, MD (KTC, EB, CG, MSK). Correspondence to: Anil K. Sood, MD, Departments of Gynecologic Oncology and Cancer Biology, The University of Texas M. D. Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030 (e-mail: asood@mdanderson.org ). See “ Notes ” following “ References. ”